1-氟-2-[2-(4-甲氧基苯基)乙烯基]苯 | 139141-12-1

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 中文名称: 1-氟-2-[2-(4-甲氧基苯基)乙烯基]苯
• 英文名称: 1-Fluoro-2-[2-(4-methoxyphenyl)ethenyl]benzene
• CAS: 139141-12-1
• 化学式: C₁₅H₁₃FO
• 分子量: 228.266
• InChiKey: ILVFNAZMSMNXJG-UHFFFAOYSA-N

物化性质

• 熔点：
  100-101 °C
• 沸点：
  340.4±11.0 °C(Predicted)
• 密度：
  1.136±0.06 g/cm3(Predicted)
• 溶解度：
  DMF：3mg/mL； DMF:PBS (pH 7.2) (1:2)：0.3 mg/mL； DMSO：2mg/mL；乙醇：0.5mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-氟-2-[2-(4-甲氧基苯基)乙烯基]苯 在 potassium sulfide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 以84%的产率得到2-(4-甲氧基苯基)苯并噻吩
  参考文献：
  名称：

  Transition-Metal-Free Method for the Synthesis of Benzo[b]thiophenes from o-Halovinylbenzenes and K2S via Direct SNAr-Type Reaction, Cyclization, and Dehydrogenation Process

  摘要：

  A new, highly efficient procedure for the synthesis of benzothiophenes from easily available o-halovinylbenzenes and potassium sulfide has been developed. The reaction tolerated a wide range of functionalities, and various 2-substituted benzo[b]thiophenes are provided in the high yields in the absence of a transition-metal catalyst.

  DOI：

  10.1055/s-0033-1339289
• 作为产物：
  描述：

  2-氟溴苄 在 potassium tert-butylate 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 11.0h， 生成 1-氟-2-[2-(4-甲氧基苯基)乙烯基]苯
  参考文献：
  名称：

  Transition-Metal-Free Method for the Synthesis of Benzo[b]thiophenes from o-Halovinylbenzenes and K2S via Direct SNAr-Type Reaction, Cyclization, and Dehydrogenation Process

  摘要：

  A new, highly efficient procedure for the synthesis of benzothiophenes from easily available o-halovinylbenzenes and potassium sulfide has been developed. The reaction tolerated a wide range of functionalities, and various 2-substituted benzo[b]thiophenes are provided in the high yields in the absence of a transition-metal catalyst.

  DOI：

  10.1055/s-0033-1339289

文献信息

• Substituted CIS- and trans-stilbenes as therapeutic agents
  申请人：Vander Jagt David L.

  公开号：US20070249647A1

  公开（公告）日：2007-10-25

  The present invention relates to method(s) of treating a subject afflicted with cancer or a precancerous condition, an inflammatory disease or condition, and/or stroke or other ischemic disease or condition, the method comprising administering to the subject or patient in need a composition comprising a therapeutically effective amount of a substituted cis or trans-stilbene.

  本发明涉及治疗患有癌症或癌前病变、炎症性疾病或病情以及中风或其他缺血性疾病或病情的方法，该方法包括向需要的受试者或患者施用含有一定治疗有效量的取代的顺式或反式-芪的组合物。
• Synthesis, structure and catalytic activity of xylylene-bridged dipalladium complexes with triazolylidene ligands
  作者：Yufeng Du、Beibei Liang、Fenglei Yang、Yanhui Shi、Xiuling Li、Guangsheng Pang、Changsheng Cao

  DOI：10.1007/s11243-016-0117-5

  日期：2017.4

  di-N-heterocyclic carbene (NHC) dipalladium complexes, [PdPyBr2]2(di-NHC) (2a–h), in which di-NHC represents a di-triazolylidene, featuring a 1,4-xylylene spacer between the carbene units, have been prepared from the reactions of the corresponding ditriazolium bromides with PdCl2 and excess NaBr as an additive in the presence of K2CO3 in pyridine. All of the complexes were fully characterized by NMR

  一系列二-N-杂环卡宾 (NHC) 二钯配合物，[PdPyBr2]2(di-NHC) (2a-h)，其中 di-NHC 代表二三唑亚基，之间有 1,4-亚二甲苯基间隔基卡宾单元是通过相应的二三唑鎓溴化物与 PdCl2 和过量的 NaBr 作为添加剂在 K2CO3 存在下在吡啶中的反应制备的。所有配合物均通过 NMR 光谱、IR 和元素分析进行​​了充分表征。通过X射线衍射研究确定了2b的分子结构，显示了Br…H–C的分子间氢键。在苯乙烯与溴苯的 Heck 反应中研究了配体大小对催化活性的影响。配合物2g表现出最好的催化活性，
• Pretargeted activatable cell penetrating peptide with intracellularly releasable prodrug
  申请人：The Regents of the University of California

  公开号：US10029017B2

  公开（公告）日：2018-07-24

  Disclosed herein, the invention pertains to methods and compositions that find use in treatment, diagnosis, prognosis and characterization of disease and disease samples based on the ability of a disease sample to cleave a MTS molecule of the present invention. The MTS molecules of the present invention have a formula as disclosed herein and wherein A is a peptide with a sequence comprising 5 to 9 consecutive acidic amino acids, wherein the amino acids are selected from: aspartates and glutamates; B is a peptide with a sequence comprising 5 to 20 consecutive basic amino acids; X and Y are linkers; P is a pre-targeting moiety; M is a macromolecular carrier, C is a detectable moiety; and T is a compound for delivery to a target, including for example a therapeutic compound.

  在此公开的本发明涉及根据疾病样本裂解本发明的 MTS 分子的能力用于疾病和疾病样本的治疗、诊断、预后和表征的方法和组合物。本发明的 MTS 分子具有如本文所公开的式，其中 A 是多肽，其序列包括 5 至 9 个连续的酸性氨基酸，其中氨基酸选自天冬氨酸和谷氨酸；B 是多肽，其序列包括 5 至 20 个连续的碱性氨基酸；X 和 Y 是连接体；P 是预靶向分子；M 是大分子载体；C 是可检测分子；T 是用于递送至靶点的化合物，例如包括治疗化合物。
• Personalized protease assay to measure protease activity in neoplasms
  申请人：The Regents of the University of California

  公开号：US10385380B2

  公开（公告）日：2019-08-20

  Disclosed herein, the invention pertains to methods and compositions that find use in diagnostic, prognostic and characterization of neoplasia samples based on the ability of a neoplasia sample to cleave a MTS molecule of the present invention. In some embodiments, a MTS molecule disclosed herein has the formula (A-X-B-C), wherein A is a peptide with a sequence comprising 5 to 9 consecutive acidic amino acids, wherein the amino acids are selected from: aspartates and glutamates; B is a peptide with a sequence comprising 5 to 20 consecutive basic amino acids; X is a linker; and C is a detectable moiety.

  本发明涉及根据肿瘤样本裂解本发明 MTS 分子的能力，用于诊断、预后和表征肿瘤样本的方法和组合物。在一些实施方案中，本发明公开的 MTS 分子具有式（A-X-B-C），其中 A 是多肽，其序列包括 5 至 9 个连续的酸性氨基酸，其中氨基酸选自天冬氨酸和谷氨酸；B 是多肽，其序列包括 5 至 20 个连续的碱性氨基酸；X 是连接体；C 是可检测分子。
• Tumor radiosensitization with monomethyl auristatin E (MMAE) and derivatives thereof
  申请人：The Regents of the University of California

  公开号：US10596259B2

  公开（公告）日：2020-03-24

  Disclosed herein, the invention pertains to methods and compositions that find use in radiosensitization of tumors and tumor samples based on the ability of a tumor sample to cleave a MTS molecule of the present invention. The MTS molecules of the present invention have a formula as disclosed herein and wherein A is a peptide with a sequence comprising 5 to 9 consecutive acidic amino acids, wherein the amino acids are selected from: aspartates and glutamates; B is a peptide with a sequence comprising 5 to 20 consecutive basic amino acids; X and Y are linkers; P is an optional pre-targeting moiety; M is an optional macromolecular carrier; and T is a radiosensitization agent for delivery to a target, including for example a therapeutic compound.

  本发明涉及根据肿瘤样品裂解本发明MTS分子的能力对肿瘤和肿瘤样品进行放射增敏的方法和组合物。本发明的MTS分子具有如本文所公开的式，其中A是具有包含5至9个连续酸性氨基酸序列的多肽，其中氨基酸选自天冬氨酸和谷氨酸；B是具有包含5至20个连续碱性氨基酸序列的多肽；X和Y是连接体；P是任选的前靶向分子；M是任选的大分子载体；T是用于递送至靶点（例如包括治疗化合物）的放射增敏剂。